This site is intended only for healthcare professionals resident in Egypt

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information

Menu

Close

Prophylaxis On-Demand Bleed Control Dosing options Clinical History Important Safety Information Abbreviated Prescribing Information

Menu

Close

Prophylaxis On-Demand Bleed Control Dosing options Clinical History Important Safety Information Abbreviated Prescribing Information
On-Demand Bleed Control

Overview

PUPs

PTPs

HeaderHeader
On-demand treatment
On-demand treatment in PTPs

of 1,796 bleeding episodes were resolved with only 1 infusion2
  On-demand treatment in PUPs
 

of 997 bleeding episodes were resolved with only 1 infusion3

FIX: factor IX; PTP: previously treated patient; PUP: previously untreated patient.

References:Benefix Egyptian Drug Authority leaflet approval date: 14/11/2021. Revision Date: November 2020.Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98(13):3600-3606.Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005;105(2):518-525.
Indicated for bleed control* in PUPs with heamophilia B2
94.1% of responses were rated excellent or good in PUPs receiving an initial infusion of BeneFIX for on-demand treatment of hemophilia B2
 
  • 2.9% of responses were rated moderate, 1% were rated as no response, 2% were not rated†2                                                                                               
  • 1505 infusions were given for on-demand treatment of 997 hemorrhages2                                                                                      
  • All bleeding episodes were controlled2                                                                          
75% of bleeds were controlled after 1 infusion with BeneFIX (n = 748)2
 
  • 14.9% were controlled after 2 infusions                                                                     
  • 5.4% were controlled after 3 infusions                                                  
  • 2.4% were controlled after 4 infusions                                                           
  • 2.2% were controlled after >4 infusions                    
BeneFIX Safety profile—supported by clinical trials in PUPs with hemophilia B2

2 out of 63 PUPs developed high-titer (>5 BU/dL) inhibitors in clinical trials.2

  • Both PUPs with high-titer inhibitors were withdrawn from the study2                                                                                   
  • The development of inhibitors occurs in 1% to 3% of patients with hemophilia B, but may be higher  in individuals with severe disease. In the current study, the incidence of FIX inhibitor was 2 of 63 (3%) patients, which is consistent with previous reports of hemophilia B patients treated with pdFIX products or PTPs treated with rFIX2
  • 56 patients received a total of 5032 infusions (mean ± SD: 89.86 ± 74.04) for a mean duration of                                                                                                                                                                   exposure of 86.75 ± 71.73 days2

Study description:

This is a multicenter, international, open-label, single-cohort study. Patients received rFIX for on-demand treatment or routine prophylaxis continued on the study for at least 2 years, up to a maximum of 5 years or 100 exposure days, whichever occurred first. Patients who completed the core phase were allowed to enter the extension phase to receive rFIX for up to 1 additional year, at the discretion of the investigator and after prior written authorization from the sponsor.2

*Study included 54 evaluable patients; median dose 62.7 IU/kg (range: 8.2-292 IU/kg).2

aEfficacy was rated by the patient/guardian or investigator using a 4-point scale of “excellent,” “good,” “moderate,” or “no response,” consistent with the rating scale used in the rFIX hemophilia clinical study of PTPs.2

FIX: factor IX; IU: international unit; pdFIX: plasma-derived factor IX; PTP: previously treated patient; PUP: previously untreated patient; rFIX: recombinant factor IX; SD: Standard Deviation.

References:Benefix Egyptian Drug Authority leaflet approval date: 14/11/2021. Revision Date: November 2020.Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005;105(2):518-525.
Indicated for bleed control in PTPs1
90.9% of responses were rated excellent or good in PTPs receiving an initial infusion of BeneFIX for on-demand treatment2                                
 
  • 7.1% were rated as moderate, 0.7% were rated as no response, 1.3% were not rated*2                                                                                                                                                                                                              
  • 2758 infusions were given for on-demand treatment of 1796 hemorrhages2                                                                                                                                                                                                                                                                                 
  • All bleeding episodes were controlled2                                                                          
   80.9% of bleeds were controlled after 1 infusion with BeneFIX2
 
  • 11.6% were controlled after 2 infusions                                                                                                    
  • 3.6% were controlled after 3 infusions                                                       
  • 1.8% were controlled after 4 infusions                                                         
  • 2.1% were controlled after >4 infusions                                                                                                                                                   
    Study included 55 evaluable patients; median dose 42.8 IU/kg (range: 6.5-224.6 IU/kg).2                
Safety in PTPs—low inhibitor formation with BeneFIX

1 out of 56 patients developed a low-titer transient inhibitor.2

Study description:

A 20-center international trial was conducted in PTPs with severe or moderate (<5 IU/dL factor IX activity) hemophilia B. Participants received rFIX for pharmacokinetic studies, treatment of or prophylaxis against hemorrhage, or surgical hemostasis, and were assessed at 3-month intervals for 2 years.2

*Bleed control rating scale: Efficacy was rated by the patient or investigator using a 4-point scale, based on a comparison with previously used pdFIX products for similar bleeds or procedures: excellent (as much and as rapid an improvement as the best pdFIX-related responses), good (as much and as rapid an improvement as most pdFIX-related responses), moderate (not as good as most pdFIX-related responses), or no response (no improvement).2

FIX: factor IX; IU: international unit; pdFIX: plasma-derived factor IX; PTP: previously treated patient; PUP: previously untreated patient; rFIX: recombinant factor IX.

References:Benefix Egyptian Drug Authority leaflet approval date: 14/11/2021. Revision Date: November 2020.Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98(13):3600-3606.
Approval No. : BV0098A2259/032022

Invalidation Date: 17/02/2025

PP-BEN-EGY-0082
Benefix Homepage

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 

 

Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.

 

PP-UNP-EGY-0064
You are leaving the Pfizer for Professionals website
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.
 
PP-UNP-EGY-0064
For Egypt Healthcare Professionals

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 If you select ""No"", you will be redirected to Pfizer.com, the global Pfoizer websitee.
 I confirm that i am a healthcare professional resident in Egypt.

Yes No